Regional radiopharmacy hubs and harmonised transport rules for short-lived isotopes
Radioactive cancer drugs decay while they travel and get stuck at borders. Regional production and simpler transport rules would get more doses to patients on time.
Overview
Radioligand therapies are often labelled centrally and shipped internationally, losing activity to decay and to customs delays; dangerous goods rules differ by country and carrier. The proposal is a network of regional GMP radiopharmacies (one per few million population) receiving bulk isotope and cold kits, labelling on demand, and delivering same-day, combined with an IAEA-brokered harmonisation of Class 7 transport paperwork and pre-clearance for medical isotopes at major airports.
- Manufacturing cost and time for living and radioactive medicines · Cell therapies take weeks to make for one patient and cost hundreds of thousands of dollars. Isotopes run short.
Similar pages
not linked directly; found by shared links- IdeaBuild Western ytterbium-176 enrichment so lutetium-177 has more than one supplier
Shares Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium, Manufacturing cost and time for living and radioactive medicines, Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan.
- IdeaA coordinated reserve and shared schedule for the world's medical isotope reactors
Shares Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium, Manufacturing cost and time for living and radioactive medicines, Radioligand therapy (beta emitters).
- InstitutionIRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)
Shares Theranostics, Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, Radioligand therapy (beta emitters).
- InstitutionInselspital, Bern University Hospital / University Cancer Center Inselspital
Shares Theranostics, Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, Radioligand therapy (beta emitters).
- IdeaA global medical isotope supply observatory with forecasts and shortage alerts
Shares Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium, Manufacturing cost and time for living and radioactive medicines, Radioligand therapy (beta emitters).
- IdeaRecover legacy radium-226 sources worldwide as the feedstock for actinium-225
Shares Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium, Manufacturing cost and time for living and radioactive medicines, Radioligand therapy (beta emitters).
- InstitutionTUM Klinikum rechts der Isar / CCC München
Shares Theranostics, Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, Radioligand therapy (beta emitters).
- InstitutionErasmus MC Cancer Institute
Shares Theranostics, Lutetium-177 dotatate, Radioligand therapy (beta emitters).